Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03229278
Title Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rutgers, The State University of New Jersey
Indications

Advanced Solid Tumor

lymphoma

Therapies

Nivolumab + Pembrolizumab + Trigriluzole

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.